One observational study [18] employed a progressive titration of biphasic insulin aspart (NovoLog® Mix 70/30; Novo Nordisk, Princeton, NJ, USA) from one up to three injections (adding one injection every 16 weeks) in patients with T2D failing OAMs with or without basal insulin, but this study did not have a comparator. The gene discussed is INS; the disease is type 2 diabetes mellitus.